Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

238.60CHF
4:30pm BST
Change (% chg)

CHF-5.70 (-2.33%)
Prev Close
CHF244.30
Open
CHF243.60
Day's High
CHF243.70
Day's Low
CHF238.60
Volume
2,734,787
Avg. Vol
1,413,993
52-wk High
CHF273.00
52-wk Low
CHF218.30

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Roche drugs chief says Ocrevus uptake to vary across countries

* CFO expects no impact from currencies on 2017 sales, core operating profit or eps

2:43pm BST

New MS drug lifts Roche as biosimilars bite in Europe

ZURICH Roche's sales rose 6 percent in the third quarter as new multiple sclerosis drug Ocrevus offset the initial blow to the Swiss-based company from copies of older, patent-expired drugs in Europe.

10:15am BST

UPDATE 2-New MS drug lifts Roche as biosimilars bite in Europe

* Roche shares down 0.6 pct (Adds Roche, analyst comments, shares and details throughout)

10:12am BST

BRIEF-Roche expects increased biosimilar impact in Q4

* Says expects impower 150 initial readout to come before end-2017 Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

7:37am BST

Roche Q3 sales beat forecasts as Ocrevus shines

ZURICH, Oct 19 Roche's third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus, the Swiss drugmaker said on Thursday.

6:19am BST

Roche's Alecensa wins EU panel's nod against mutated lung cancer

ZURICH Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.

13 Oct 2017

Roche's Alecensa wins EU panel's nod against mutated lung cancer

ZURICH Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.

13 Oct 2017

Roche's Alecensa wins EU panel's nod against mutated lung cancer

ZURICH, Oct 13 Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.

13 Oct 2017

'Double whammy' for Roche as manufacturing patent losses loom

ZURICH Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed.

12 Oct 2017

'Double whammy' for Roche as manufacturing patent losses loom

ZURICH, Oct 12 Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed.

12 Oct 2017

Earnings vs. Estimates